Biocrine

Biocrine is a Swedish life-science company based in Solna, Sweden, dedicated to the discovery and commercialization of new concepts for treating diabetes and the complications the disease induces. Its research pipeline is rooted in the study of the pancreatic gland — specifically the endocrine pancreas and the islets of Langerhans — and the interplay of hormones, receptors and other molecules that regulate metabolism. The company states that its goal is to commercialize new concepts of treatment and to enable continuous delivery of novel drugs both for diabetes itself and for the complications that this disease induces. The scientific foundation of Biocrine comes from the Rolf Luft Research Center for Diabetes and Endocrinology at Karolinska Institutet, described by the company as one of the world's leading research institutes focused on the endocrine part of the pancreas. Professor Per-Olof Berggren, a world-leading scientist in the interpretation of the mechanisms controlling hormone release in the endocrine pancreas, leads the research effort, together with Professor emeritus Suad Efendic. Their team has made pioneering discoveries in diabetes research using advanced technologies in biochemistry, cellular biology, electrophysiology and molecular biology. Biocrine aims to commercialize six patented research programs: Serum factor ApoCIII, insulin receptor isoforms, calcium channels, and inositol polyphosphates, among others. In addition to its drug-development programs, the company promotes the InSight Technology, which offers a unique opportunity to study molecular processes within a living cell. Following transplantation of a cell cluster into an eye, cellular activity can be observed in real time with a specifically designed microscope system. The company is headquartered in Solna, Sweden, and operates primarily in the Swedish life-science ecosystem, drawing on academic research partnerships. It is a private company and maintains an active research and news presence through its official website.

Biocrine was established to commercialize discoveries made at the Rolf Luft Research Center for Diabetes and Endocrinology at Karolinska Institutet in Sweden. The center is described by the company as one of the world's leading research institutes focusing on the endocrine part of the pancreas — the islets of Langerhans. The scientific team, led by Professor Per-Olof Berggren and Professor emeritus Suad Efendic, has worked in this field for decades and has made a number of pioneering discoveries in diabetes research using advanced technologies in biochemistry, cellular biology, electrophysiology and molecular biology. The company's mission is to commercialize new concepts of treatment and enable continuous delivery of novel drugs both for diabetes itself and for the complications that the disease induces. Its research focuses on understanding what happens in the pancreatic gland, including the role and interplay of hormones, receptors and other molecules, based on the belief that every molecular event is important in the development of this complex disease. Biocrine aims to commercialize six patented research programs, including Serum factor ApoCIII, insulin receptor isoforms, calcium channels and inositol polyphosphates. The company also developed and promotes the InSight Technology, which allows real-time observation of molecular processes within a living cell after transplantation of a cell cluster into an eye, using a specifically designed microscope system. Biocrine is headquartered in Solna, Sweden, and remains an active private research company, publishing news and research updates on its official website.

• Research programs established based on discoveries at the Rolf Luft Research Center, Karolinska Institutet

• InSight Technology developed for real-time intraocular cell imaging

• Six patented research programs identified for commercialization

Academic spin-out translating basic diabetes research from Karolinska Institutet into patented therapeutic concepts and imaging technology.

• Serum factor ApoCIII

• Insulin receptor isoforms

• Calcium channels

• Inositol polyphosphates

• InSight Technology

1. 1BioCrine official websitebiocrine.com
2. 2About Us | BioCrinebiocrine.com
3. 3Company and people | BioCrinebiocrine.com
4. 4Biocrine (Sweden) - Wikidatawikidata.org